Use

Merz Aesthetics Highlights Emerging Trends in Regenerative Aesthetics and its Innovative Portfolio at the 2023 Aesthetic and Anti-aging Medicine World Congress (AMWC)

Retrieved on: 
Wednesday, March 29, 2023
Science, Other Science, Biotechnology, Surgery, Health, Cosmetics, Retail, Other Health, Abstract, Medical Affairs Bureau, Merz Aesthetics Women's Challenger, Use, Aesthetics, Efficacy, Ageing, Research, Ultrasound, Interference, Melasma, Visualization, Congress, Merz, Micro, Interior design, Industrial design, Medical imaging, Medical device

Merz Aesthetics, a global leader in aesthetic medicine, is presenting a total of 15 posters at the 2023 Aesthetic and Anti-Aging Medicine World Congress (AMWC), highlighting its medical aesthetics product portfolio as well as new trends in aesthetic medicine.

Key Points: 
  • Merz Aesthetics, a global leader in aesthetic medicine, is presenting a total of 15 posters at the 2023 Aesthetic and Anti-Aging Medicine World Congress (AMWC), highlighting its medical aesthetics product portfolio as well as new trends in aesthetic medicine.
  • AMWC is a leading global scientific conference specializing in aesthetic and anti-aging medicine, and this year’s congress will be a hybrid event allowing participants to attend live in Monaco or virtually from March 30 until April 1, 2023.
  • “Merz Aesthetics is looking forward to highlighting our advancing science and leadership within the medical aesthetics industry at this year’s AMWC, including insights on the evolving field of regenerative aesthetics,” said Terri Phillips, M.D., Chief Medical Affairs Officer, Merz Aesthetics.
  • This includes two Merz Aesthetics’ sponsored symposium events.

AN2 Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights

Retrieved on: 
Wednesday, March 29, 2023
Biotechnology, FDA, Health, General Health, Public Relations, Investor Relations, Pharmaceutical, Communications, Research, Infectious Diseases, Science, Clinical Trials, Infectious Diseases Society of America, Use, Interest, AN2, Civil service commission, Alcohol dehydrogenase, National Institute of Allergy and Infectious Diseases, Infection, Medicines and Healthcare products Regulatory Agency, Clinical research associate, Clinical trial, Trial of the century, Pharmacokinetics, Global health, IDSA, ID, MAC, NTM, Nontuberculous mycobacteria, Patient, Investment, Administration, PMDA, ADH, European, Diagnosis, Entrepreneurship, Mortality, Research and development, Therapy, R, Conference, European Commission, Safety, Pharmaceutical industry, Video game, Fine chemical, Cryptocurrency

AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today reported financial results for the fourth quarter and year ended December 31, 2022.

Key Points: 
  • AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today reported financial results for the fourth quarter and year ended December 31, 2022.
  • R&D expenses for the fourth quarter of 2022 were $8.7 million, compared to $5.8 million for the same period last year.
  • General and administrative expenses for the fourth quarter of 2022 were $3.7 million, compared to $1.8 million for the same period last year.
  • Interest and other income, net for the fourth quarter of 2022 was $0.6 million, compared to $0.05 million for the fourth quarter of 2021.

Insider voted #1 Leader with the highest user satisfaction score (98/100) in G2's Spring'23 Reports across seven categories, including Personalization, Mobile Marketing, and Customer Data Platforms

Retrieved on: 
Thursday, March 30, 2023
Momentum, Spend, WhatsApp, Mixpanel, Partnership, MoEngage, Insider, Mobile marketing, Personal software process, Use, AMP, Integration, Predictive modelling, Amplitude, Brazing, Customer data platform, CDPS, Ease, Automation, Index, SMS, History, Marketing, CleverTap, CRM, CDP, Cause of action, Software product management, Science Citation Index Expanded, Marketing automation, ROI, Mobile app, Mobile phone, Sales, Retail, Online shopping, G2, Segment, Revenue Analytics

Insider also topped the Momentum Grid in Marketing Automation, proving itself the fastest-growing and most robust cross-channel journey orchestration solution.

Key Points: 
  • Insider also topped the Momentum Grid in Marketing Automation, proving itself the fastest-growing and most robust cross-channel journey orchestration solution.
  • Insider's Customer Data Platform is not a traditional CDP that unifies customer data and creates multiple segments.
  • Insider has all the makings to stitch together scattered anonymous and known data into actionable customer data profiles."
  • Insider continues to expand its product suite to help brands deliver more individualized experiences to drive higher and faster ROI.

LiDAR for Automotive Market Size is estimated to grow by USD 4.60 billion from 2023 to 2029, propelling Growth Due to Rising Research & Development for autonomous vehicles

Retrieved on: 
Wednesday, March 29, 2023
Research report, Use, Electronics, Build automation, Automotive industry, USD, Car, Investment, PUNE, ADAS, Laser, Environment, MOD, Safety, Bridge, Surveying, Lidar

PUNE, India, March 29, 2023 /PRNewswire/ -- Exactitude Consultancy, the market research and consulting wing of Ameliorate Digital Consultancy Private Limited has completed and published the final copy of the detailed research report on the LiDAR for Automotive Market.

Key Points: 
  • The global LiDAR for Automotive market is expected to grow at a CAGR of 17% from 2022 to 2029, from USD 1.12 billion in 2020 to USD 4.60 billion in 2029.
  • Autonomous vehicles are in high demand, and technological advances have made this a real-world possibility, with many vehicle manufacturers investing in the development of such vehicles.
  • LiDAR sensors are critical components of critical systems such as blind-spot monitoring, lane-keep assistance, lane-departure warning, and collision warning in autonomous vehicles.
  • These investments are anticipated to stimulate innovation in LiDAR technology, leading to LiDAR sensors that work better and are more cost-effective.

LiDAR for Automotive Market Size is estimated to grow by USD 4.60 billion from 2023 to 2029, propelling Growth Due to Rising Research & Development for autonomous vehicles

Retrieved on: 
Wednesday, March 29, 2023
Research report, Use, Electronics, Build automation, Automotive industry, USD, Car, Investment, PUNE, ADAS, Laser, Environment, MOD, Safety, Bridge, Surveying, Lidar

PUNE, India, March 29, 2023 /PRNewswire/ -- Exactitude Consultancy, the market research and consulting wing of Ameliorate Digital Consultancy Private Limited has completed and published the final copy of the detailed research report on the LiDAR for Automotive Market.

Key Points: 
  • The global LiDAR for Automotive market is expected to grow at a CAGR of 17% from 2022 to 2029, from USD 1.12 billion in 2020 to USD 4.60 billion in 2029.
  • Autonomous vehicles are in high demand, and technological advances have made this a real-world possibility, with many vehicle manufacturers investing in the development of such vehicles.
  • LiDAR sensors are critical components of critical systems such as blind-spot monitoring, lane-keep assistance, lane-departure warning, and collision warning in autonomous vehicles.
  • These investments are anticipated to stimulate innovation in LiDAR technology, leading to LiDAR sensors that work better and are more cost-effective.

FPF Report: Not-So-Standard Clauses – An Examination of Three Regional Contractual Frameworks for International Data Transfers

Retrieved on: 
Thursday, March 30, 2023
Transfer, FPF, EU, Use, ASEAN, MTA, Contract, Privacy, Ibero-America, Future of Privacy Forum, Government, SCCS, Collection, Council, Hitachi HD44780 LCD controller, GDPR, International Data Group, Risk management

FPF Report: Not-So-Standard Clauses – An Examination of Three Regional Contractual Frameworks for International Data Transfers

Key Points: 
  • FPF Report: Not-So-Standard Clauses – An Examination of Three Regional Contractual Frameworks for International Data Transfers
    On March 30, the Future of Privacy Forum launched a new report comparing three regional model contractual frameworks for cross-border data transfers.
  • The report compares the EU’s Standard Contractual Clauses (SCCs), the ASEAN Model Contractual Clauses (MCCs), and the Iberoamerican Network’s Model Transfer Agreement (MTA).
  • International transfers of personal information are an increasingly contentious space in the privacy and data protection world.
  • Exceptions to those restrictions go hand-in-hand with those generalized restrictions on cross-border data transfers; in that context, pre-approved contractual frameworks between transferor and transferee have emerged as critical components of the modern cross-border data transfer environment.

JOURNAL OF MEDICAL INTERNET RESEARCH | CAN ARTIFICIAL INTELLIGENCE BE USED TO DIAGNOSE INFLUENZA?

Retrieved on: 
Tuesday, March 28, 2023
Telehealth, Medicine, Use, Pharynx, Journal of Medical Internet Research, Disease, Deep learning, COVID-19, Research, Publication, Epidemic, Report, Pandemic, Hospital, Journal, MD, Patient, Polymerase chain reaction, Physician, Risk, Diagnosis, AI, PCR, Global Burden of Disease Study, Vaccine, Medical imaging, Medical device

TORONTO and PHILADELPHIA, March 28, 2023 /PRNewswire/ -- JMIR Publications published "Examining the Use of an Artificial Intelligence Model to Diagnose Influenza: Development and Validation Study" in the Journal of Medical Internet Research, which reported that it may be possible to diagnose influenza infection by applying deep learning to pharyngeal images given that influenza primarily infects the upper respiratory system.

Key Points: 
  • These authors aimed to develop a deep learning model to diagnose influenza infection using pharyngeal images and clinical information.
  • In the training stage, the authors developed a diagnostic prediction artificial intelligence (AI) model based on deep learning to predict polymerase chain reaction (PCR)-confirmed influenza from pharyngeal images and clinical information.
  • This process led to the development of the first AI model that can accurately diagnose influenza.
  • Dr Okiyama and the research team concluded in their JMIR Publications Research Article , "we developed the first AI-assisted diagnostic camera for influenza and prospectively validated its high performance.

New CPSC Report Shows Upward Trend in Carbon Monoxide (CO) Fatalities

Retrieved on: 
Tuesday, March 28, 2023
Carbon, CPSC, Use, Weakness, Person, Ventilation, U.S. Consumer Product Safety Commission, Death, CO, Dizziness, Poisoning, Consumer, Nausea, Carbon monoxide, Work & Co, Safety, EDT Hub, Coal, Pharmaceutical industry, Heating, ventilation, and air conditioning

WASHINGTON, March 28, 2023 /PRNewswire/ -- The U.S. Consumer Product Safety Commission (CPSC) today released a new report that shows an upward trend in non-fire carbon monoxide (CO) poisoning deaths. The report, Non-Fire Carbon Monoxide Deaths Associated with the Use of Consumer Products 2019 Annual Estimates, covers deaths from 2009 to 2019.

Key Points: 
  • WASHINGTON, March 28, 2023 /PRNewswire/ -- The U.S. Consumer Product Safety Commission (CPSC) today released a new report that shows an upward trend in non-fire carbon monoxide (CO) poisoning deaths.
  • The report, Non-Fire Carbon Monoxide Deaths Associated with the Use of Consumer Products 2019 Annual Estimates , covers deaths from 2009 to 2019.
  • For 2019, there were an estimated 250 consumer product-related CO deaths in the United States - greater than any other year in the report.
  • Engine-Driven Tools (EDTs), including generators, were associated with the largest percentage of non-fire CO poisoning deaths for 2019.

Rhythm Pharmaceuticals Announces Publication of Bardet-Biedl Syndrome Patient and Caregiver Perspectives of Hunger and Quality of Life with Setmelanotide

Retrieved on: 
Monday, March 27, 2023
Polyphagia, Faculty, University of Alberta, Obesity, Food, University, Use, Phase II, Stroke, Weight loss, Bardet–Biedl syndrome, Eating, Quality of life, Advances in Therapy, Research, BBS, Patient, Child, MC4R, University of Melbourne Faculty of Medicine, Dentistry and Health Sciences, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Caregiver, Medicine, Pharmaceutical industry, Residential care, Rhythm, Syndrome, Hunger

BOSTON, March 27, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases, today announced the publication of interview-based patient and caregiver reported experiences of hunger and quality of life with setmelanotide treatment in Bardet-Biedl syndrome (BBS). The research is published in the peer-reviewed journal Advances in Therapy.

Key Points: 
  • A total of 19 interviews were conducted with patients (n=8) and caregivers (n=11) to explore patient experience and caregiver observations of hyperphagia before and during setmelanotide treatment.
  • Before setmelanotide treatment, most patients (n=7; 87.5%) and caregivers (n=10; 90.9%) experienced negative effects directly related to hyperphagia.
  • “Until now, the impact of hyperphagia on the lives of these patients and their families has not been fully understood.
  • These data can be incorporated into cost-utility models conducted to assess the value of treatments for rare MC4R pathway diseases.

Digital Diagnostics Sheds Light on AI Tech with LumineticsCore™ Product Rebrand

Retrieved on: 
Tuesday, March 28, 2023
Retina, Use, Jean-Pierre Luminet, Cybernetics, Marketing, Engle, Eye, Core, Light, Science, Creativity, Name, Patient, Diagnosis, AI, Medical device, Medical imaging

CORALVILLE, Iowa, March 28, 2023 /PRNewswire/ -- Digital Diagnostics – a leading AI diagnostics company on a mission to transform global healthcare – has rebranded its flagship product, the AI diagnostic system formerly known as IDx-DR, to LumineticsCore™.

Key Points: 
  • CORALVILLE, Iowa, March 28, 2023 /PRNewswire/ -- Digital Diagnostics – a leading AI diagnostics company on a mission to transform global healthcare – has rebranded its flagship product, the AI diagnostic system formerly known as IDx-DR, to LumineticsCore™.
  • The "Core" identifier denotes LumineticsCore as the first in the Luminetics product line and represents the central nature of the flagship diagnostic system within the Digital Diagnostics suite of products.
  • Adding identifiers to current and future product brand names provides clarity for users as well as product brand differentiation in the market.
  • A newly designed LumineticsCore logo serves as a visual representation of the holistic approach that Digital Diagnostics brings to healthcare.